TrialRMD open2025

Sustained resolution of enthesitis and peripheral arthritis over 104 weeks with bimekizumab in axial spondyloarthritis.

Sofia Ramiro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.